Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
Zacks.com on MSN2d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
And Cerevel Therapeutics, which had positive early testing results for emraclidine, its drug that aims to treat schizophrenia ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Disappointing news from the laboratory weighed on AbbVie (NYSE: ABBV) stock as the trading week kicked off. The company had high hopes for a schizophrenia drug it was developing; however, it did not ...
Steve Grzanich has the business news of the day with the Wintrust Business Minute. Shares of AbbVie have dropped sharply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback